Table 1.

Labeled and off-labeled indications of MMF.

Indication	Studies
Labeled (FDA Approved) Indications	Studies that led to FDA approvals
Renal transplant	Sollinger 1995 [24], Grinyo 1995 [25], Keown 1996 [26]
Liver transplant	Eckhoff 1998 [27], Wiesner 2005 [28], Nashan 2009 [29]
Cardiac transplant	Eisen 2005 [30], Kobashigawa 2006 [31], Kaczarek 2013 [32], Andreassen 2014 [33]
Off-Label Use	Studies supporting off-label use
Lung transplant	Treede 2001 [34], Zuckermann 2003 [35], Speich 2010 [36]
Pancreatic transplant	Ricart 2012 [37], Descourouez 2018 [38]
Refractory acute graft-versus-host disease	Alousi 2009 [39]
Refractory chronic graft-versus-host disease	Wolff 2010 [40]
Prevention of graft-versus-host disease	Sabry 2009 [41]
Aplastic anemia	Scheinberg 2006 [42]
Autoimmune hepatitis, first line	Zachou 2016 [43]
Refractory autoimmune hepatitis	Manns 2010 [44]
Lupus nephritis	Contreras 2004 [45], Ong 2005 [46], Dooley 2011 [47], Hahn 2012 [48]
Myasthenia gravis	Meriggiolo 2003 [49], Sanders 2016 [50], Sieb 2014 [51]
Psoriasis	Menter 2009 [52]
Systemic sclerosis	Gerbino 2008 [53], Derk 2009 [54], Le 2011 [55], Mendoza 2012 [56], Tashkin 2016 [57], Herrick 2017 [58]